Bionxt Solutions Inc (TSE:BNXT) has released an update.
BioNxt Solutions Inc. has announced promising results from a pharmacokinetic study of its oral dissolvable film Cladribine, showing effective drug delivery for the treatment of Multiple Sclerosis. The company’s product demonstrated rapid absorption comparable to the reference drug, positioning BioNxt to advance into human trials and expand its drug formulations. With Cladribine’s global market presence and the MS drug market projected to grow, BioNxt is actively pursuing product development and patent filings.
For further insights into TSE:BNXT stock, check out TipRanks’ Stock Analysis page.
